Showing results (81-90 of 237) with videos related to

Sort By:
Pageof 24
Leukemia Research|December 3, 2019
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trialElias Jabbour, Nicola Gökbuget, Anjali Advani, et al.
Haematologica|April 12, 2012
Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II studyBirgit Federmann, Martin Bornhauser, Christoph Meisner, et al.
Blood|December 7, 2007
Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomographyMatthias Stelljes, Sven Hermann, Jörn Albring, et al.
American Journal of Hematology|January 10, 2019
Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicinElias Jabbour, Anjali S Advani, Matthias Stelljes, et al.
Bone Marrow Transplantation|February 1, 2020
Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemiaKlaus Wethmar, Svenja Matern, Eva Eßeling, et al.
Haematologica|December 5, 2024
Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell TherapyWolfgang Bethge, Sarah Flossdorf, Franziska Hanke, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 11, 2019
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationOlle Ringdén, Ariane Boumendil, Myriam Labopin, et al.
Haematologica|June 1, 2023
Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-TrialThomas Schroeder, Matthias Stelljes, Maximilian Christopeit, et al.
Molecular and Cellular Biology|March 17, 2004
Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cellsCarsten Müller-Tidow, Björn Steffen, Thomas Cauvet, et al.
European Journal of Haematology|May 24, 2018
Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosisSharifah Shahnaz Syed Abd Kadir, Maximilian Christopeit, Gerald Wulf, et al.
Pageof 24